In the news | 1st March 2022
Advances in Biologics Require Advances in Data Management
Throughout the past few years, there’s been a clear trend in the makeup of approvals, with biologics representing a growing percentage. But even within biologics, newer technologies like mRNA, cell, and gene therapies are gaining ground. The approvals are not one-off events, but evidence of an exciting long-term trend. Learn more from Christian Marcazzo, General Manager at IDBS, in his article published in Drug Development & Discovery.